Chugai’s 9-Month Sales Up 17.5% on Ronapreve, 42.8 Billion Yen Booked in Govt Purchase

Chugai Pharmaceutical saw its revenue surge 17.5% in the first nine-month period of 2021 thanks to the contribution from its COVID-19 antibody cocktail Ronapreve (casirivimab + imdevimab), which logged 42.8 billion yen in sales to the Japanese government. In January-September,...read more